Patterns of withdrawal in patients with opioid use disorder (OUD) transitioning from untreated OUD or buprenorphine treatment to extended-release naltrexone

被引:1
|
作者
Mannelli, Paolo [1 ]
Douaihy, Antoine B. [2 ]
Zavod, Abigail [3 ]
Legedza, Anna [4 ]
Akerman, Sarah C. [5 ]
Sullivan, Maria A. [5 ,6 ]
机构
[1] Duke Univ, Dept Psychiat & Behav Sci, Med Ctr, 2213 Elba St,Ste 156,DUMC 3074, Durham, NC 27705 USA
[2] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA
[3] Alkermes Inc, Clin Res, Waltham, MA USA
[4] Alkermes Inc, Biostat, Waltham, MA USA
[5] Alkermes Inc, Med Affairs, Waltham, MA USA
[6] Columbia Univ, Dept Psychiat, New York, NY USA
来源
AMERICAN JOURNAL OF DRUG AND ALCOHOL ABUSE | 2021年 / 47卷 / 06期
关键词
Antagonist; maintenance; opioid discontinuation; partial agonist; substance use; INPATIENT;
D O I
10.1080/00952990.2021.1969659
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
Background Pharmacologic treatment is recommended for many individuals with opioid use disorder (OUD). For patients who select opioid antagonist treatment, effective management of opioid withdrawal symptoms during transition to antagonist treatment requires consideration of the patient experience. Objectives To compare patterns of opioid withdrawal between those withdrawing from untreated opioid use and those withdrawing from buprenorphine. Methods We performed a post hoc, cross-study comparison of the temporal pattern of opioid withdrawal during 1-week induction onto extended-release naltrexone by similar protocols enrolling two participant populations: participants with OUD entering a study with untreated opioid use (N = 378, NCT02537574) or on stable buprenorphine (BUP) treatment (N = 101, NCT02696434). Results The temporal pattern of withdrawal from induction day 1 through day 7 differed between the two participant populations for Clinical Opiate Withdrawal Score (COWS) and Subjective Opiate Withdrawal Score (SOWS): participants with untreated OUD prior to study entry were more likely to experience an earlier relative peak in opioid withdrawal followed by a gradual decline, whereas participants on stable BUP treatment prior to study entry were more likely to experience a relatively later, though still mild, peak opioid withdrawal. The peak COWS was reached at a mean (standard deviation) of 1.9 (1.5) days for participants with untreated OUD and 5.0 (1.5) days for participants on stable BUP. Daily peak cravings were generally higher for participants with untreated OUD than participants on stable BUP. Conclusion Awareness of population-specific variations in the patient experience of opioid withdrawal may help clinicians anticipate the expected course of withdrawal.
引用
收藏
页码:753 / 759
页数:7
相关论文
共 50 条
  • [31] Personal recovery among people with opioid use disorder during treatment with extended-release naltrexone
    Marciuch, Anne
    Birkeland, Bente
    Benth, Jurate Saltyte
    Solli, Kristin Klemmetsby
    Tanum, Lars
    Mathisen, Ida
    Weimand, Bente
    HELIYON, 2023, 9 (07)
  • [32] Case series: Voluntary discontinuation of sublingual buprenorphine treatment for opioid use disorder using extended-release buprenorphine
    Rodriguez, Claudia P.
    Suzuki, Joji
    AMERICAN JOURNAL ON ADDICTIONS, 2023, 32 (03): : 314 - 317
  • [33] Reduced cigarette smoking during injectable extended-release naltrexone treatment for opioid use disorder
    Wang An-Li
    Shi Zhenhao
    Elman, Igor
    Langleben, Daniel D.
    AMERICAN JOURNAL OF DRUG AND ALCOHOL ABUSE, 2020, 46 (04): : 472 - 477
  • [34] Long-Term Prospects for Telemedicine in Opioid Use Disorder (OUD) Treatment: Results from a Longitudinal Survey of OUD Clinicians
    Huskamp, Haiden A.
    Riedel, Lauren
    Campa, Isabella
    Busch, Alisa B.
    Rose, Sherri
    Mehrotra, Ateev
    Uscher-Pines, Lori
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2023, 38 (09) : 2139 - 2146
  • [35] Association between methadone or buprenorphine use during medically supervised opioid withdrawal and extended-release injectable naltrexone induction failure
    Shulman, Matisyahu
    Choo, Tse-Hwei
    Scodes, Jennifer
    Pavlicova, Martina
    Wai, Jonathan
    Haenlein, Patrick
    Tofighi, Babak
    Campbell, Aimee N. C.
    Lee, Joshua D.
    Rotrosen, John
    Nunes, Edward V.
    JOURNAL OF SUBSTANCE ABUSE TREATMENT, 2021, 124
  • [36] Depression and Suicidal Ideation in Adults With Opioid Use Disorder Treated With Buprenorphine-Naloxone Versus Extended-Release Naltrexone
    Rizk, Mina
    Stanley, Barbara
    Choo, Tse-Hwei
    Pavilcova, Martina
    Scodes, Jennifer
    Campbell, Aimee
    Nunes, Edward
    Rotrosen, John
    BIOLOGICAL PSYCHIATRY, 2020, 87 (09) : S268 - S269
  • [37] Long-Term Prospects for Telemedicine in Opioid Use Disorder (OUD) Treatment: Results from a Longitudinal Survey of OUD Clinicians
    Haiden A. Huskamp
    Lauren Riedel
    Isabella Campa
    Alisa B. Busch
    Sherri Rose
    Ateev Mehrotra
    Lori Uscher-Pines
    Journal of General Internal Medicine, 2023, 38 : 2139 - 2146
  • [38] Psychoeducational Strategies During Outpatient Transition to Extended-Release Naltrexone for Patients With Opioid Use Disorder
    Zavod, Abigail
    Akerman, Sarah C.
    Snow, Martha M.
    Tierney, Matt
    Sullivan, Maria A.
    JOURNAL OF THE AMERICAN PSYCHIATRIC NURSES ASSOCIATION, 2019, 25 (04) : 272 - 279
  • [39] Extended-release naltrexone for opioid use disorder started during or following incarceration
    Lincoln, Thomas
    Johnson, Benjamin D.
    McCarthy, Patrick
    Alexander, Ellen
    JOURNAL OF SUBSTANCE ABUSE TREATMENT, 2018, 85 : 97 - 100
  • [40] An Emulated Trial of Buprenorphine-Naloxone Versus Extended-Release Naltrexone Following Medically Managed Opioid Withdrawal
    Larochelle, Marc
    Yan, Shapei
    Christine, Paul
    Bovell-Ammon, Benjamin
    Bernson, Dana
    Liebschutz, Jane
    Walley, Alexander
    Novo, Patricia
    Lee, Joshua D.
    Rotrosen, John
    Lodi, Sara
    DRUG AND ALCOHOL DEPENDENCE, 2025, 267